Global Pharmaceutical And Biotechnology Market Companies
Companies such as, Novartis AG, GSK plc, Merck KGaA, AstraZeneca, Siemens Healthineers AG, and others are involved in the biotechnology and pharmaceutical industry. Strategic alliances, a focus on R&D, strong regulatory compliance, relationship-building, a rise in innovation and R&D, and the use of digital platforms for outreach are all components of the plan of action that these businesses are implementing.
List of Key Players in the Market:
- Novartis AG
- GSK plc.
- Merck KGaA
- AstraZeneca
- Siemens Healthineers AG
- Parexel International (MA) Corporation
- Eli Lilly and Company
- Aragen Life Sciences Ltd.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Amgen Inc.
- Genentech, Inc.
- UCB S.A.
- Sai Life Sciences Limited
Recent News:
- A pharmaceutical firm called Lupin was given permission by the US health government to sell a generic HIV drug in the U.S. market, in January 2025. The US Food and Drug Administration (USFDA) granted the business a provisional permission for the use of Abacavir, Dolutegravir, and Lamivudine tablets under the US President's Emergency Plan for AIDS Relief (PEPFAR).
- The biotechnology business Bharat Biotech International Ltd., which produces vaccines, introduced a new single-stain oral cholera vaccine (OCV) called Hillchol (BBV131), in August 2024. The Wellcome Trust in the UK and Merck in the USA provided funding for its development, which was licensed from Hilleman Laboratories.
- The world's top biopharma research marketplace, Scientist.com, has announced the release of Elisa, a new research assistant driven by large language models (LLMs), in June 2024. For scientists working in the biotechnology and pharmaceutical sectors, Elisa was the most recent in a series of exclusive AI-powered applications.
- BMF Biotechnology Inc. was established by Boston Micro Fabrication (BMF) with the goal of creating and promoting cutting-edge BioChips (organ-on-a-chip platforms) by growing large-scale tissues in vitro, which would hasten the creation of novel medications and cosmetics, in May 2024. Additionally, this firm contributed to the progress of biotechnology and pharmaceuticals.
- The goal of SCHOTT Pharma's expansion in the United States was to produce prefillable polymer syringes, which are necessary for the shipping and deep-cold storage of mRNA drugs, in March 2024. Glass prefillable syringes for GLP-1 treatments were also expected to be produced at the location.